التفاصيل البيبلوغرافية
| العنوان: |
Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. |
| المؤلفون: |
Baloni, Priyanka, Arnold, Matthias, Buitrago, Luna, Nho, Kwangsik, Moreno, Herman, Huynh, Kevin, Brauner, Barbara, Louie, Gregory, Kueider-Paisley, Alexandra, Suhre, Karsten, Saykin, Andrew J., Ekroos, Kim, Meikle, Peter J., Hood, Leroy, Price, Nathan D., The Alzheimer's Disease Metabolomics Consortium, Blach, Colette, Kaddurah-Daouk, Rima, Doraiswamy, Murali, Mahmoudiandehkordi, Siamak |
| المصدر: |
Communications Biology; 10/8/2022, Vol. 5 Issue 1, p1-13, 13p |
| مصطلحات موضوعية: |
ALZHEIMER'S disease, METABOLIC flux analysis, SPHINGOMYELIN, CERAMIDES, DRUG target |
| مستخلص: |
Dysregulation of sphingomyelin and ceramide metabolism have been implicated in Alzheimer's disease. Genome-wide and transcriptome-wide association studies have identified various genes and genetic variants in lipid metabolism that are associated with Alzheimer's disease. However, the molecular mechanisms of sphingomyelin and ceramide disruption remain to be determined. We focus on the sphingolipid pathway and carry out multi-omics analyses to identify central and peripheral metabolic changes in Alzheimer's patients, correlating them to imaging features. Our multi-omics approach is based on (a) 2114 human post-mortem brain transcriptomics to identify differentially expressed genes; (b) in silico metabolic flux analysis on context-specific metabolic networks identified differential reaction fluxes; (c) multimodal neuroimaging analysis on 1576 participants to associate genetic variants in sphingomyelin pathway with Alzheimer's disease pathogenesis; (d) plasma metabolomic and lipidomic analysis to identify associations of lipid species with dysregulation in Alzheimer's; and (e) metabolite genome-wide association studies to define receptors within the pathway as a potential drug target. We validate our hypothesis in amyloidogenic APP/PS1 mice and show prolonged exposure to fingolimod alleviated synaptic plasticity and cognitive impairment in mice. Our integrative multi-omics approach identifies potential targets in the sphingomyelin pathway and suggests modulators of S1P metabolism as possible candidates for Alzheimer's disease treatment. Complementary multi-omics approach, in silico metabolic flux, and neuroimaging analyses link the sphingolipid pathway to Alzheimer's disease pathogenesis with therapeutic targets validated using behavioral assessments in amyloidogenic APP/PS1 mice. [ABSTRACT FROM AUTHOR] |
|
Copyright of Communications Biology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder